Morgan Stanley upgraded BioAge Labs (BIOA) to Equal Weight from Underweight with a price target of $12, up from $5, after the company announced interim Phase 1 data for BGE-102, including safety info and data from single and multiple ascending doses up to 120mg in healthy volunteers. The initial “encouraging” clinical data for BGE-102 highlights robust biomarker reductions, suggesting potential to reduce cardiovascular risk, contends the analyst, who will look to additional data in 2026 for further confirmation.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA:
- Positive Developments and Promising Trials Bolster Buy Rating for BioAge Labs
- BioAge Labs Announces Positive Phase 1 Trial Results
- BioAge Labs announces interim Phase 1 data for BGE-102
- BioAge Labs Advances Clinical Programs Amid Financial Progress
- BioAge Labs price target raised to $15 from $10 at Citi